eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

6/2022
vol. 14
 
Share:
Share:
more
 
 
abstract:
Original paper

Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study

Mengjie Li
1
,
Peng Liu
1
,
Huan Wang
1
,
Biao Wang
1
,
Jie Zhou
1
,
Yuzhen Jin
1
,
Cuicui Wang
1
,
Jian Yang
2
,
Ping Zhang
2

1.
Department of Respiratory and Critical Care Medicine, Cangzhou Fifth Hospital (People’s Hospital of Qingxian), Cangzhou 062650, China
2.
Precision Radiotherapy Center, Cangzhou People’s Hospital, Cangzhou 061001, China
J Contemp Brachytherapy 2022; 14, 6: 536–541
Online publish date: 2022/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
To explore the efficacy of computed tomography (CT)-guided iodine-125 (125I) radioactive seed implantation for the treatment of small-cell lung cancer (SCLC).

Material and methods
A total of 12 SCLC patients were retrospectively enrolled. All patients underwent CT-guided 125I seed implantation therapy, and were followed up until death, the last visit time, or study end time. Primary endpoint was the overall response rate (ORR). Secondary endpoints were local control rate (LCR), progression-free survival (PFS), overall survival (OS), and safety.

Results
All patients were successfully implanted with 125I radioactive seeds. The ORR at 2, 6, 12, and 24 months after implantation was 83.3%, 63.6%, 50%, and 40%, respectively; the LCR at 1 and 2 years were 75% (6/8) and 60% (3/5), respectively; the median PFS and OS were 8 and 12 months, respectively; and the OS rate at 6, 12, and 24 months after implantation was 91.67%, 66.67%, and 41.67%, respectively. No surgery-related deaths occurred. During the follow-up period, mild complications were observed in patients, including worsening cough, hemoptysis, and pneumothorax.

Conclusions
CT-guided 125I seed implantation therapy is a safe and effective supplementary treatment for SCLC patients, who cannot tolerate radiotherapy.

keywords:

small-cell lung cancer, iodine-125 radioactive seed implantation, computed tomography-guided, brachytherapy

 
Quick links
© 2023 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.